The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Is MRD ready to be used in the clinic to guide CLL treatment decisions?
Paul Hengeveld, MD, PhD, Erasmus University, Rotterdam, Netherlands, discusses if measurable residual disease (MRD) is ready to be used in clinical practice for chronic lymphocytic leukemia (CLL). He also discusses how MRD can be used to guide treatment decisions. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
